Document Detail


Oxidative stress and erythrocyte acetylcholinesterase (AChE) in hypertensive and ischemic patients of both acute and chronic stages.
MedLine Citation:
PMID:  18031975     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ischemic stroke is a leading cause of mortality and disability particularly in the elderly. Hypertension is the most important risk factor in strokes, representing roughly 70% of all cases. Oxidative stress is believed to be one of the mechanisms taking part in neuronal damage in stroke. It is well documented that cholinergic system plays a key role in normal brain functions and in memory disturbances of several pathological processes, such as in cerebral blood flow regulation. This study investigated the oxidative status and acetylcholinesterase (AChE) activity in whole blood in patients diagnosed with acute and chronic stages of ischemia, as well as with hypertension. Malondialdehyde (MDA) levels and protein carbonylation content showed increased levels both in the acute ischemic groups and in the hypertensive group, when compared to the control. Catalase activity and reduced glutathione (GSH) levels in the acute group were also higher than in the hypertensive, chronic ischemic and control groups (p<0.05). The activity of AChE in acute ischemic patients was significantly higher than that presented by the control, hypertensive and chronic ischemic patients (p<0.05). The hypertensive group presented AChE activity significantly lower than control and chronic groups. In spite of having a defined location the ischemic event results in a systemic disorder that induces changes, which can be detected by measuring the peripheral markers of oxidative stress and AChE activity in erythrocytes.
Authors:
Maísa de Carvalho Corrêa; Paula Maldonado; Cíntia Saydelles da Rosa; Gilberto Lunkes; Daniele Sausen Lunkes; Rosilene Rodrigues Kaizer; Mushtaq Ahmed; Vera Maria Morsch; Maria Ester Pereira; Maria Rosa Schetinger
Related Documents :
3611765 - The use of doppler echocardiography to assess the acute haemodynamic response to felodi...
16191235 - Prevention of stroke recurrence.
10376845 - Homocysteine, hypertension and stroke.
12658005 - International society of hypertension (ish): statement on blood pressure lowering and s...
15372385 - Combination of intraneural injection and high injection pressure leads to fascicular in...
17315605 - The genetic basis for altered blood vessel function in disease: large artery stiffening.
Publication Detail:
Type:  Journal Article     Date:  2007-10-30
Journal Detail:
Title:  Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie     Volume:  62     ISSN:  0753-3322     ISO Abbreviation:  Biomed. Pharmacother.     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-06-03     Completed Date:  2008-10-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8213295     Medline TA:  Biomed Pharmacother     Country:  France    
Other Details:
Languages:  eng     Pagination:  317-24     Citation Subset:  IM    
Affiliation:
Departamento de Química, Programa de Pós-Graduação em Bioquímica Toxicológica, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, Campus Camobi, 97105-900 Santa Maria, RS, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetylcholinesterase / blood*
Acute Disease
Aged
Antioxidants / metabolism
Brain Ischemia / complications*
Catalase / blood
Chronic Disease
Erythrocytes / enzymology*
Glutathione / blood
Humans
Hypertension / metabolism*
Lipid Peroxidation
Middle Aged
Oxidative Stress*
Protein Carbonylation
Stroke / etiology,  metabolism*
Thiobarbituric Acid Reactive Substances / metabolism
Chemical
Reg. No./Substance:
0/Antioxidants; 0/Thiobarbituric Acid Reactive Substances; 70-18-8/Glutathione; EC 1.11.1.6/Catalase; EC 3.1.1.7/Acetylcholinesterase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antimycobacterial activities of novel fluoroquinolones.
Next Document:  Natalizumab in multiple sclerosis: the second treatment revolution